ECEESPE2025 Poster Presentations Endocrine Related Cancer (76 abstracts)
Plasma concentrations of selected growth factors as a potential tool for detecting recurrence in endocrine tumors - a pilot study
Marta Opalinska 1 , Anna Kurzyńska 1 , Karolina Morawiec-Slawek 1 , Agnieszka Stefańska 2 , Magdalena Kolasa 2 , Edyta Tkacz 2 , Małgorzata Szumińska 2 , Anna Sowa-Staszczak 1 , Justyna Brodowicz 3 , Katarzyna Gawlik 3 , Dorota Pawlica-Gosiewska 3 , Bogdan Solnica 3 & Alicja Hubalewska-Dydejczyk 1
1Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland; 2Department of Endocrinology, Oncological Endocrinology, Nuclear Medicine and Internal Medicine, University Hospital in Krakow, Kraków, Poland; 3Department of Clinical Biochemistry, Jagiellonian University Medical College, Kraków, Poland
JOINT1757
Introduction: The current standard of care for patients with endocrine neoplasms emphasizes the personalization of diagnostic and therapeutic approaches. Several key time points are critical, including the early detection of recurrence following radical surgery. While thyroglobulin is used for thyroid cancer and calcitonin for medullary thyroid cancer, robust tumor markers are unfortunately unavailable for other types of endocrine neoplasms, such as neuroendocrine tumors and pheochromocytomas. It appears that certain growth factors involved in tumorigenesis could potentially serve as useful markers for detecting recurrence of these tumors. The aim of this study is to determine whether any of the selected growth factors (TNF-α, Fascin, VEGF, Galectin-1, Galectin-3, and FGF), measured in the serum of patients with disseminated endocrine neoplasms, could serve as potential markers for recurrence.
Methods: The study included 43 patients with disseminated endocrine neoplasms (30 with neuroendocrine tumors (NET), 6 with medullary thyroid cancer (MTC), and 7 with adrenal neoplasms) and 25 healthy controls. Serum levels of TNF-α, Fascin, VEGF, Galectin-1, Galectin-3, and FGF were measured in all patients and healthy controls using ELISA assays. The biochemical analysis results were compared across the different patient subsets with various endocrine neoplasms and the control group.
Results: A comparison of all patients with disseminated endocrine neoplasms and the control group revealed significant differences in TNF-α levels (2. 88 vs. 0. 93 [ng/mL], P = 0. 008). When comparing the concentrations of the measured factors between subgroups (classified by tumor type) and the control group, differences were found for TNF-α (P = 0. 007) and Fascin (P = 0. 035). For Fascin, significant differences were observed between MTC patients and those with adrenal neoplasms (0. 52 vs. 5. 28 [ng/mL], P = 0. 048), as well as between MTC and NET patients (0. 52 vs. 5. 59 [ng/mL], P = 0. 007). The difference between NET patients and controls was nearly significant (5. 59 vs. 3. 67 [ng/mL], P = 0. 076). For TNF-α, significant differences were found between NET patients and controls (2. 88 vs. 0. 03 [ng/mL], P = 0. 005) as well as between MTC patients and controls (2. 77 vs. 0. 93 [ng/mL], P = 0. 004).
Conclusion: Plasma concentrations of selected growth factors (TNF-α, Fascin) differ between healthy individuals and those with disseminated endocrine neoplasms. Further research is needed to evaluate their potential in detecting recurrence of NET and MTC.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more